The DEEP project has received research funding from the European Union under the 7th Framework Programme
The following objectives are addressed in the present WP:
• to develop and prepare a drug product suitable for the paediatric population with a small weight range
• to develop a -80 mg/mL oral solution that is more palatable than the one currently on the market
WP Leader: John Connelly (Apotex)
Involved Partners: CVBF, ApoPharma, Apotex, UKER